| (KLEM-ass-teen FEW-muh-rate) |
| Dayhist-1 |
| Tablets |
| 1.34 mg as fumarate (equiv. to 1 mg clemastine) |
| Tavist Allergy |
| Tablets |
| 1.34 mg as fumarate (equiv. to 1 mg clemastine) |
| Clemastine Fumarate |
| Tablets |
| 2.68 mg (equiv. to 2 mg clemastine) |
| Syrup |
| 0.67 mg/5 mL (equiv. to 0.5 mg clemastine) |
Tavist, Tavist-1 |
| Class: Antihistamine, Ethanolamine |
Action Competitively antagonizes histamine at H1 receptor sites.
Indications Relief of symptoms associated with allergic rhinitis or other upper respiratiry allergies, such as sneezing, rhinorrhea, pruritus, and lacrimation; relief of mild, uncomplicated allergic skin manifestation of urticaria and angioedema.
Contraindications Hypersensitivity to antihistamines; narrow-angle glaucoma; stenosing peptic ulcer; symptomatic prostatic hypertrophy; asthmatic attack; bladder neck obstruction; pyloroduodenal obstruction; MAO inhibitor therapy; use in newborn or premature infants and in nursing women.
Adults and Children over 12 yr: PO 1.34 mg bid to 2.68 mg tid (max, 8.04 mg/day).
Children 6 to 12 yr: PO (syrup only) 0.67 to 1.34 mg bid (max, 4.02 mg/day).
Alcohol, CNS depressants: May cause additive CNS depressant effects.
MAO Inhibitors: May increase anticholinergic effects of clemastine fumarate.
Skin testing procedures: Drug may prevent or diminish otherwise positive reaction to dermal reactivity indicators.
CARDIOVASCULAR: Orthostatic hypotension; palpitations; bradycardia; tachycardia; arrhythmias. CNS: Drowsiness (often transient); sedation; dizziness; faintness; disturbed coordination.EENT: Blurred vision; tinnitus. GI: Epigastric distress; nausea; vomiting; diarrhea; constipation. HEMATOLOGIC: Hemolytic anemia; thrombocytopenia; agranulocytosis. METABOLIC: Increased appetite; weight gain. RESPIRATORY: Thickening of bronchial secretions; chest tightness; wheezing; nasal stuffiness; dry mouth, nose and throat; sore throat; respiratory depression. OTHER: Hypersensitivity reactions; photosensitivity.
Pregnancy: Category B. Lactation: Contraindicated in nursing mothers. Children: Safety and efficacy in children less than 12 yr not established. Elderly: Elderly and debilitated patients are at an increased risk of dizziness, excessive sedation, syncope, toxic confusional states, and hypotension. Dosage reduction may be required. Special risk patients: Use drug with caution in patients predisposed to urinary retention, history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, or hypertension. Avoid use in patients with history of sleep apnea. Hepatic impairment: Use with caution in patients with cirrhosis or other liver disorders.
| PATIENT CARE CONSIDERATIONS |
|
|
||||
Popularity: 3% [?]
RSS feed for comments on this post · TrackBack URI
Leave a reply